Hypertrophic obstructive cardiomyopathy. [PDF]
openaire +3 more sources
Myosin Inhibition in Non-obstructive Hypertrophic Cardiomyopathy: Lessons from ODYSSEY-HCM. [PDF]
Hasegawa K, Iguchi M, Wada H, Dan GA.
europepmc +1 more source
Methodological Considerations on Targeted Polymer Embolization in Obstructive Hypertrophic Cardiomyopathy. [PDF]
Kivrak A +3 more
europepmc +1 more source
Real-World Evaluation of Guideline-Directed Treatments in Patients With Obstructive Hypertrophic Cardiomyopathy in Germany. [PDF]
Sedaghat-Hamedani F +9 more
europepmc +1 more source
Still at sea: a patient's ongoing journey with non-obstructive hypertrophic cardiomyopathy. [PDF]
Goldie FC, Myles RC, Coats CJ.
europepmc +1 more source
Impact of Sociodemographic Characteristics on Outcomes in Obstructive Hypertrophic Cardiomyopathy. [PDF]
Reza N +6 more
europepmc +1 more source
INFECTIVE ENDOCARDITIS DUE TO GEMELLA-MORBILLORUM COMPLICATING HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY [PDF]
Kerr, JR +3 more
core +2 more sources
Cost-effectiveness of aficamten for obstructive hypertrophic cardiomyopathy: a model-based analysis from the perspective of the Chinese healthcare system. [PDF]
Zhai F +5 more
europepmc +1 more source
Evaluation of the effect of mavacamten on left ventricular function in obstructive hypertrophic cardiomyopathy using myocardial work. [PDF]
Wan L +5 more
europepmc +1 more source
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study. [PDF]
Tower-Rader A +21 more
europepmc +1 more source

